Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1982 1
1984 4
1985 3
1986 8
1987 6
1988 9
1989 22
1990 24
1991 26
1992 28
1993 40
1994 53
1995 62
1996 63
1997 72
1998 84
1999 80
2000 87
2001 91
2002 72
2003 118
2004 115
2005 127
2006 146
2007 154
2008 191
2009 209
2010 241
2011 253
2012 269
2013 267
2014 260
2015 232
2016 217
2017 218
2018 211
2019 195
2020 209
2021 167
2022 143
2023 142
2024 47

Text availability

Article attribute

Article type

Publication date

Search Results

4,404 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Progesterone Receptor Expressing Malignant Neoplasm"
Page 1
The Role of Progesterone Receptors in Breast Cancer.
Li Z, Wei H, Li S, Wu P, Mao X. Li Z, et al. Drug Des Devel Ther. 2022 Jan 26;16:305-314. doi: 10.2147/DDDT.S336643. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35115765 Free PMC article. Review.
The progesterone receptor (PR) modulates estrogen receptors alpha (ERalpha) action in breast cancer; it is an upregulated target gene of ER, and its expression is dependent on estrogen. PR is also a valuable prognostic biomarker in breast cancer …
The progesterone receptor (PR) modulates estrogen receptors alpha (ERalpha) action in breast cancer; it is an upregulat …
The T47D cell line is an ideal experimental model to elucidate the progesterone-specific effects of a luminal A subtype of breast cancer.
Yu S, Kim T, Yoo KH, Kang K. Yu S, et al. Biochem Biophys Res Commun. 2017 May 6;486(3):752-758. doi: 10.1016/j.bbrc.2017.03.114. Epub 2017 Mar 22. Biochem Biophys Res Commun. 2017. PMID: 28342866
In this study, we compared the genome-wide binding profiles of ERalpha, PR, and P300, and the gene expression changes between MCF-7 and T47D cell lines that represent the luminal A subtype of breast cancer. ...Consistently, changes in the expression level of …
In this study, we compared the genome-wide binding profiles of ERalpha, PR, and P300, and the gene expression changes between …
Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact?
Kunc M, Biernat W, Senkus-Konefka E. Kunc M, et al. Cancer Treat Rev. 2018 Jun;67:78-87. doi: 10.1016/j.ctrv.2018.05.005. Epub 2018 May 16. Cancer Treat Rev. 2018. PMID: 29772460 Review.
The estrogen receptor alpha (ER) and the progesterone receptor (PgR) are one of the most important prognostic and predictive immunohistochemical markers in breast cancer. Breast cancers may express various profiles of hormone receptors: E …
The estrogen receptor alpha (ER) and the progesterone receptor (PgR) are one of the most important prognostic and pr …
Characterizing Clinicopathologic Features of Estrogen Receptor-Positive/Progesterone Receptor-Negative Breast Cancers.
Fei F, Siegal GP, Wei S. Fei F, et al. Clin Breast Cancer. 2022 Oct;22(7):e788-e797. doi: 10.1016/j.clbc.2022.07.001. Epub 2022 Jul 9. Clin Breast Cancer. 2022. PMID: 35915022
BACKGROUND: While most estrogen receptor-positive (ER+) breast cancers express progesterone receptor (PR), a small subset of tumors exhibits an ER+/PR- phenotype despite the fact that PR is an ER-dependent gene product. ...Further, the ER+/PR- t …
BACKGROUND: While most estrogen receptor-positive (ER+) breast cancers express progesterone receptor (PR), a sma …
Biological markers of invasive breast cancer.
Matsumoto A, Jinno H, Ando T, Fujii T, Nakamura T, Saito J, Takahashi M, Hayashida T, Kitagawa Y. Matsumoto A, et al. Jpn J Clin Oncol. 2016 Feb;46(2):99-105. doi: 10.1093/jjco/hyv153. Epub 2015 Oct 20. Jpn J Clin Oncol. 2016. PMID: 26486826 Review.
Biological markers for breast cancer are biomolecules that result from cancer-related processes and are associated with particular clinical outcomes; they thus help predict responses to therapy. In recent years, gene expression profiling has made the molecula …
Biological markers for breast cancer are biomolecules that result from cancer-related processes and are associated with particular clinical …
Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis.
Luo H, Li S, Zhao M, Sheng B, Zhu H, Zhu X. Luo H, et al. Oncotarget. 2017 May 30;8(22):36845-36856. doi: 10.18632/oncotarget.15982. Oncotarget. 2017. PMID: 28415663 Free PMC article. Review.
Subgroup analysis showed that progesterone receptor expression was associated with a favorable prognosis of unclassified ovarian cancer, European origin, and immunohistochemical detection method. CONCLUSION: Progesterone receptor expression …
Subgroup analysis showed that progesterone receptor expression was associated with a favorable prognosis of unclassifie …
Expression of Estrogen Receptor- and Progesterone Receptor-Regulating MicroRNAs in Breast Cancer.
Kalinina T, Kononchuk V, Alekseenok E, Obukhova D, Sidorov S, Strunkin D, Gulyaeva L. Kalinina T, et al. Genes (Basel). 2021 Apr 16;12(4):582. doi: 10.3390/genes12040582. Genes (Basel). 2021. PMID: 33923732 Free PMC article.
In ~70% of breast cancer (BC) cases, estrogen and progesterone receptors (ER and PR) are overexpressed, which can change during tumor progression. Expression changes of these receptors during cancer initiation and progression can be caused by alteratio …
In ~70% of breast cancer (BC) cases, estrogen and progesterone receptors (ER and PR) are overexpressed, which can change durin …
Alternative splicing and the progesterone receptor in breast cancer.
Cork DM, Lennard TW, Tyson-Capper AJ. Cork DM, et al. Breast Cancer Res. 2008;10(3):207. doi: 10.1186/bcr2097. Epub 2008 May 30. Breast Cancer Res. 2008. PMID: 18557990 Free PMC article. Review.
Progesterone receptor negative tumours have generally been shown to have a poorer prognosis than progesterone receptor positive tumours. The observed loss of progesterone receptor could be through a range of mechanisms, including t …
Progesterone receptor negative tumours have generally been shown to have a poorer prognosis than progesterone recept …
Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis.
Shiino S, Ball G, Syed BM, Kurozumi S, Green AR, Tsuda H, Takayama S, Suto A, Rakha EA. Shiino S, et al. Breast Cancer Res Treat. 2022 Jan;191(1):1-14. doi: 10.1007/s10549-021-06390-6. Epub 2021 Oct 6. Breast Cancer Res Treat. 2022. PMID: 34613502 Free PMC article. Review.
PURPOSE: This meta-analysis aimed to investigate whether receptor (estrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor 2 [HER2]) discordances between primary and recurrent breast cancers affect patients …
PURPOSE: This meta-analysis aimed to investigate whether receptor (estrogen receptor [ER], progesterone receptor …
Biomarker assessment and molecular testing for prognostication in breast cancer.
Kos Z, Dabbs DJ. Kos Z, et al. Histopathology. 2016 Jan;68(1):70-85. doi: 10.1111/his.12795. Histopathology. 2016. PMID: 26768030 Review.
Current treatment of breast cancer incorporates clinical, pathological and molecular data. Oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) define prognosis and identify tumours for targeted therap …
Current treatment of breast cancer incorporates clinical, pathological and molecular data. Oestrogen receptor (ER), progesterone …
4,404 results